Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease

Brain Research Reviews

Volumn 48, Issue 2, 2005, Pages 400-408

  Gasparini, Laura ^a,b   Ongini, Ennio ^a   Wilcock, Donna ^c   Morgan, David ^c  

^a NicOx Research Institute   (Italy)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer's disease; Flurbiprofen; HCT 1026; Microglia; NCX 2216; NSAIDs

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; IBUPROFEN; INDOMETACIN DERIVATIVE; MECLOFENAMIC ACID; NAPROXEN; NCX 2216; NITRIC OXIDE DONOR; PARACETAMOL; PIROXICAM; SC 125; SULINDAC; SULINDAC SULFONE;

ALZHEIMER DISEASE; CELL ACTIVATION; CONFERENCE PAPER; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEVER; GASTROINTESTINAL DISEASE; HUMAN; INFLAMMATION; MEDICAL INFORMATION; MICROGLIA; PAIN; PRIORITY JOURNAL; REDUCTION; RISK FACTOR;

EID: 17844374592     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2004.12.029     Document Type: Conference Paper

References (50)

1. P.S. Aisen, K.A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, K.L. Davis, M.R. Farlow, S. Jin, R.G. Thomas, and L.J. Thal Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial JAMA 289 2003 2819 2826
2. M.A. Ajmone-Cat, A. Nicolini, and L. Minghetti Differential effects of the nonsteroidal antiinflammatory drug flurbiprofen and its nitric oxide-releasing derivative, nitroflurbiprofen, on prostaglandin E(2), interleukin-1beta, and nitric oxide synthesis by activated microglia J. Neurosci. Res. 66 2001 715 722
3. H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole, N.R. Cooper, P. Eikelenboom, M. Emmerling, B.L. Fiebich, C.E. Finch, S. Frautschy, W.S. Griffin, H. Hampel, M. Hull, G. Landreth, L.-F. Lue, R. Mrak, I.R. Mackenzie, P.L. McGeer, M.K. O'Banion, J. Pachter, G. Pasinetti, C. Plata-Salaman, J. Rogers, R. Rydel, Y. Shen, W. Streit, R. Strohmeyer, I. Tooyoma, F.L. Van Muiswinkel, R. Veerhuis, D. Walker, S. Webster, B. Hauss-Wegrzyniak, G. Wenk, and T. Wyss-Coray Inflammation and Alzheimer's disease Neurobiol. Aging 21 2000 383 421
4. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, I. Lieberburg, R. Motter, M. Nguyen, F. Soriano, N. Vasquez, K. Weiss, B. Welch, P. Seubert, D. Schenk, and T. Yednock Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat. Med. 6 2000 916 919
5. P. Eikelenboom, C. Bate, W.A. Van Gool, J.J. Hoozemans, J.M. Rozemuller, R. Veerhuis, and A. Williams Neuroinflammation in Alzheimer's disease and prion disease Glia 40 2002 232 239
6. J.L. Eriksen, S.A. Sagi, T.E. Smith, S. Weggen, P. Das, D.C. McLendon, V.V. Ozols, K.W. Jessing, K.H. Zavitz, E.H. Koo, and T.E. Golde NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ 42 in vivo J Clin. Invest 112 2003 440 449
7. J.L. Eriksen, M.M. Nicolle, S. Prescott, V.V. Ozols, J.M. Zhuo, T.E. Monnier, J.L. Beard, S. Weggen, S.A. Sagi, E.H. Koo, and T.E. Golde Chronic treatment of transgenic APP mice with R-flurbiprofen Abstract Viewer/Itinerary Planner 2003 Society for Neuroscience Washington, DC Program No. 295.22. 2003
8. M. Etminan, S. Gill, and A. Samii Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies BMJ 327 2003 128 132
9. R.J. Flower The development of COX2 inhibitors Nat. Rev., Drug Discov. 2 2003 179 191
10. J.C. Frolich A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes Trends Pharmacol. Sci. 18 1997 30 34
11. H.M. Gao, B. Liu, W. Zhang, and J.S. Hong Novel anti-inflammatory therapy for Parkinson's disease Trends Pharmacol. Sci. 24 2003 395 401
12. L. Gasparini, L. Rusconi, H. Xu, P. del Soldato, and E. Ongini Modulation of β-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures J. Neurochem. 88 2004 337 348
13. L. Gasparini, E. Ongini, and G.L. Wenk Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action J. Neurochem. 91 2004 521 536
14. J.P. Greenfield, R.S. Gross, G.K. Gouras, and H. Xu Cellular and molecular basis of β-amyloid precursor protein metabolism Front. Biosci. 5 2000 D72 D83
15. B. Hauss-Wegrzyniak, L.B. Willard, P. Del Soldato, G. Pepeu, and G.L. Wenk Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS Brain Res. 815 1999 36 43
16. B. Hauss-Wegrzyniak, P. Vraniak, and G.L. Wenk The effects of a novel NSAID on chronic neuroinflammation are age dependent Neurobiol. Aging 20 1999 305 313
17. B. in't Veld, A. Ruitenberg, A. Hofman, L.J. Launer, C.M. van Duijn, T. Stijnen, M.M. Breteler, and B.H. Stricker Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease N. Engl. J. Med. 345 2001 1515 1521
18. B. in 't Veld, L.J. Launer, M.M. Breteler, A. Hofman, and B.H. Stricker Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence Epidemiol. Rev. 24 2002 248 268
19. P.T. Jantzen, K.E. Connor, G. DiCarlo, G.L. Wenk, J.L. Wallace, A.M. Rojiani, D. Coppola, D. Morgan, and M.N. Gordon Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice J. Neurosci. 22 2002 2246 2254
20. A. Klegeris, J. Maguire, and P.L. McGeer S- but not R-enantiomers of flurbiprofen and ibuprofen reduce human microglial and THP-1 cell neurotoxicity J. Neuroimmunol. 152 2004 73 77
21. T.A. Lanz, G.J. Fici, and K.M. Merchant Lack of specific Aβ(1-42) suppression by NSAIDs in young, claque-free Tg2576 mice and in guinea pig neuronal cultures J. Pharmacol. Exp. Ther. 312 2004 399 406
22. G.P. Lim, F. Yang, T. Chu, P. Chen, W. Beech, B. Teter, T. Tran, O. Ubeda, K.H. Ashe, S.A. Frautschy, and G.M. Cole Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease J. Neurosci. 20 2000 5709 5714
23. G.P. Lim, T. Chu, F. Yang, W. Beech, S.A. Frautschy, and G.M. Cole The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse J. Neurosci. 21 2001 8370 8377
24. G.P. Lim, F. Yang, T. Chu, E. Gahtan, O. Ubeda, W. Beech, J.B. Overmier, K. Hsiao-Ashe, S.A. Frautschy, and G.M. Cole Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice Neurobiol. Aging 22 2001 983 991
25. E.G. McGeer, and P.L. McGeer Inflammatory processes in Alzheimer's disease Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 2003 741 749
26. D. Morgan, and B.D. Gitter Evidence supporting a role for anti-Aβ antibodies in the treatment of Alzheimer's disease Neurobiol. Aging 25 2004 605 608
27. T. Morihara, T. Chu, O. Ubeda, W. Beech, and G.M. Cole Selective inhibition of Aβ42 production by NSAID R-enantiomers J. Neurochem. 83 2002 1009 1012
28. E.E. Netland, J.L. Newton, R.E. Majocha, and B.A. Tate Indomethacin reverses the microglial response to amyloid β-protein Neurobiol. Aging 19 1998 201 204
29. J.M. Orgogozo, S. Gilman, J.F. Dartigues, B. Laurent, M. Puel, L.C. Kirby, P. Jouanny, B. Dubois, L. Eisner, S. Flitman, B.F. Michel, M. Boada, A. Frank, and C. Hock Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization Neurology 61 2003 46 54
30. C. Prosperi, C. Scali, M. Barba, A. Bellucci, M. Giovannini, G. Pepeu, and F. Casamenti Comparison between flurbiprofen and its nitric oxide-releasing derivatives HCT1026 and NCX2216 on Abeta(1-42)-induced brain inflammation and neuronal damage in the rat Int. J. Immunol. Pharmacol. 17 2004 317 330
31. J. Quinn, T. Montine, J. Morrow, W.R. Woodward, D. Kulhanek, and F. Eckenstein Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease J. Neuroimmunol. 137 2003 32 41
32. S.A. Reines, G.A. Block, J.C. Morris, G. Liu, M.L. Nessly, C.R. Lines, B.A. Norman, and C.C. Baranak Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study Neurology 62 2004 66 71
33. J.B. Rich, D.X. Rasmusson, M.F. Folstein, K.A. Carson, C. Kawas, and J. Brandt Nonsteroidal anti-inflammatory drugs in Alzheimer's disease Neurology 45 1995 51 55
34. J. Rogers, L.C. Kirby, S.R. Hempelman, D.L. Berry, P.L. McGeer, A.W. Kaszniak, J. Zalinski, M. Cofield, L. Mansukhani, and P. Willson Clinical trial of indomethacin in Alzheimer's disease Neurology 43 1993 1609 1611
35. S. Rosi, K. McGann, B. Hauss-Wegrzyniak, and G.L. Wenk The influence of brain inflammation upon neuronal adenosine A2B receptors J. Neurochem. 86 2003 220 227
36. S. Scharf, A. Mander, A. Ugoni, F. Vajda, and N. Christophidis A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease Neurology 53 1999 197 201
37. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T. Yednock, D. Games, and P. Seubert Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 1999 173 177
38. C. Schwab, M. Hosokawa, and P.L. McGeer Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease Exp. Neurol. 188 2004 52 64
39. I. Tegeder, E. Niederberger, E. Israr, H. Guhring, K. Brune, C. Euchenhofer, S. Grosch, and G. Geisslinger Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen FASEB J. 15 2001 2 4
40. T. Van Groen, and I. Kadish Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology Brain Res. Rev. 2004 (in press)
41. J.L. Wallace, G. Cirino, G.W. McKnight, and S.N. Elliott Reduction of gastrointestinal injury in acute endotoxic shock by flurbiprofen nitroxybutylester Eur. J. Pharmacol. 280 1995 63 68
42. J.L. Wallace, M.N. Muscara, G. de Nucci, S. Zamuner, G. Cirino, P. Del Soldato, and E. Ongini Gastric tolerability and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen derivative, NCX-2216 [3-[4-(2-fluoro-alpha-methyl-[1,1′-biphenyl]-4-acetyloxy)-3- methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester] J. Pharmacol. Exp. Ther. 309 2004 626 633
43. S. Weggen, J.L. Eriksen, P. Das, S.A. Sagi, R. Wang, C.U. Pietrzik, K.A. Findlay, T.E. Smith, M.P. Murphy, T. Bulter, D.E. Kang, N. Marquez-Sterling, T.E. Golde, and E.H. Koo A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity Nature 414 2001 212 216
44. G.L. Wenk, K. McGann-Gramling, B. Hauss-Wegrzyniak, D. Ronchetti, R. Maucci, S. Rosi, L. Gasparini, and E. Ongini Attenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acid J. Neurochem. 89 2004 484 493
45. D.M. Wilcock, G. DiCarlo, D. Henderson, J. Jackson, K. Clarke, K.E. Ugen, M.N. Gordon, and D. Morgan Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation J. Neurosci. 23 2003 3745 3751
46. D.M. Wilcock, S.K. Munireddy, A. Rosenthal, K.E. Ugen, M.N. Gordon, and D. Morgan Microglial activation facilitates Aβ plaques removal following intracranial anti-Aβ antibody administration Neurobiol. Dis. 15 2004 11 20
47. D.M. Wilcock, A. Rojiani, A. Rosenthal, G. Levkowitz, S. Subbarao, J. Alamed, D. Wilson, N. Wilson, M.J. Freeman, M.N. Gordon, and D. Morgan Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition J. Neurosci. 24 2004 6144 6151
48. T. Wyss-Coray, and L. Mucke Inflammation in neurodegenerative disease-a double-edged sword Neuron 35 2002 419 432
49. J.J. Yan, J.Y. Cho, H.S. Kim, K.L. Kim, J.S. Jung, S.O. Huh, H.W. Suh, Y.H. Kim, and D.K. Song Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid Br. J. Pharmacol. 133 2001 89 96
50. Q. Yan, J. Zhang, H. Liu, S. Babu-Khan, R. Vassar, A.L. Biere, M. Citron, and G. Landreth Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease J. Neurosci. 23 2003 7504 7509